This report was first published by Endpoints News. To see the original version, click here
Vinay PrasadVinay Prasad’s second exit from FDA leadership after less than a year in his positions didn’t come as a major surprise. But with his two positions now left to fill — as the director of CBER and as chief medical and scientific officer — there are questions about the agency’s future direction with vaccine and rare disease drug reviews.
您已阅读10%（437字），剩余90%（3820字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。